REN001

DRUG3 trials

Sponsors

Reneo Pharma Ltd

Conditions

McArdle DiseasePrimary Mitochondrial Myopathy

Phase 1

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

TerminatedNCT03862846

Reneo Pharma LtdPrimary Mitochondrial Myopathy

Start: 2019-05-10End: 2020-04-23Updated: 2020-07-16

A Study of the Safety of REN001 in Patients With McArdle Disease

CompletedNCT04226274

Reneo Pharma LtdMcArdle Disease

Start: 2019-12-10End: 2021-10-11Updated: 2022-01-12

Phase 2

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

TerminatedNCT05267574

Reneo Pharma LtdPrimary Mitochondrial Myopathy

Start: 2022-02-01End: 2024-01-31Updated: 2024-05-28